Navigation Links
CryoLife to Present at Sidoti's 13th Annual New York Emerging Growth Institutional Forum
Date:3/19/2009

ATLANTA, March 19 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and tissue processing company, announced today that it will participate in the Sidoti & Company, LLC 13th Annual New York Emerging Growth Institutional Forum at The Grand Hyatt Hotel on Wednesday, March 25, 2009.

D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present a corporate overview at 2:05 p.m. Eastern Time.

A copy of CryoLife's slide presentation will be posted the day of the presentation on the Investor Relations page of www.cryolife.com.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom, Germany, France, and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.

For additional information about the Company, visit CryoLife's Web Site: http://www.cryolife.com.


'/>"/>

SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
2. CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
3. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
4. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
5. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
6. CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2008 Financial Results
7. CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure
8. CryoLife Expands Distribution of Hemostase MPH(R) to Canada through Sorin Group Canada, Inc.
9. CryoLife to Present at UBS Global Life Sciences Conference
10. CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida
11. CryoLife Announces Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 EPFL ... announce the appointment of John P. Donoghue . ...   in  Geneva . The new ... Biotech in Geneva , has named ... neuroscientists. John P. Donoghue , founder of Brown ...
(Date:7/10/2014)... July 10, 2014 Women in ... access to an additional family planning option. Sayana® ... contraception at all levels of the health system ... of a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone ... Faso is the first of four African countries ...
(Date:7/10/2014)... Boston, Mass. (PRWEB) July 10, 2014 ... , today announced that Alan Swahn, a former vice ... Terascala’s executive team as vice president of marketing. Terascala’s ... from Dell and NetApp create the highest performance and ... has been appointed to guide Terascala’s channel expansion and ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... , BOTHELL, Wash., Aug. 7 SCOLR Pharma, ... for the three and six months ended June 30, 2009. ... President and CEO, said, "We continue to advance discussions with a ... potential partners have been committing resources to due diligence and preliminary ...
... HUNTSVILLE, Ala., Aug. 7 EGEN, Inc. (EGEN), a biopharmaceutical ... that Jason Fewell, Ph.D., has been promoted from Director of ... , , Dr. Fewell possesses more than ... industry and has served at EGEN since 2003 as Director ...
... BRISBANE, Calif., Aug. 7 InterMune, Inc. (Nasdaq: ... Officer and President of InterMune, will present at the Canaccord Adams ... at 10:30 a.m. EDT. , , To access ... parties may log on to the investor relations page of InterMune,s ...
Cached Biology Technology:SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 8EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development 2
(Date:7/11/2014)... risk of kidney injury related to the use of ... of HES molecules, according to a report in ... Anesthesia Research Society (IARS). , The "total mass of ... cultured human renal proximal tubule cells (PTCs), concludes the ... University Hospital Wrzburg, Austria. Other factorssuch as differences ...
(Date:7/11/2014)... the hippocampus, the marginal division of the striatum ... is the impact degree of substance P in ... function? Yan Yu and his team, College of ... immunofluorescence staining, that substance P receptor, neurokinin 1 ... marginal division of normal rats. Unilateral or bilateral ...
(Date:7/11/2014)... receptor type 1 can inhibit voltage-gated calcium ... neurotransmitter release. However, some scholars demonstrated that ... Ca2+ influx and increase neurotransmitter release. Dr. ... Affiliated to Tongji Medical College, Huazhong University ... cell voltage-clamp and calcium imaging in cultured ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... Ohio Researchers, health care engineers and medical ... National Conference on Value-driven Engineering to Improve Medical ... Austen BioInnovation Institute in Akron (ABIA) and sponsored ... some of the nation,s leading biomedical device engineering ...
... many aspects of who we are from the colour ... but how are the genes, and consequently the proteins they ... new group of molecules which control some of the fundamental ... developing new therapies for treating neurodegenerative diseases. The research, ...
... in German . Leipzig/Dresden/Freiburg. In recent ... around the world. As a team of researchers from the ... Dresden and the University of Freiburg headed by the UFZ ... global pollination benefit" in the open-access journal PLoS ONE ...
Cached Biology News:Medical device, health professionals attend first national conference on value-driven engineering 2Medical device, health professionals attend first national conference on value-driven engineering 3Doubling the information from the double helix 2Global prices of pollination-dependent products such as coffee could rise in the long term 2Global prices of pollination-dependent products such as coffee could rise in the long term 3
5 minutes from gel band to purified DNA...
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-MSC 2 x 109 cells...
... Agarose overlays are commonly ... Many commercial "DNA grade" agaroses ... toxic to insect cells or ... to obtain good overlays. Novagen's ...
AgarPlaque Plus Agarose 50 grams...
Biology Products: